Askan Schultze-Mosgau

No ORCID on file · 5 papers in corpus
nonrandomized-trial 2013
Archives of gynecology and obstetrics ·doi:10.1007/s00404-013-2794-z

PURPOSE: In the GnRH-antagonist protocol, ovarian stimulation with gonadotropins typically commences on cycle day 2 or 3. Initiation of ovarian stimulation with a spontaneously occurring menstruation, however, poses significant organization…

review 2006
Expert opinion on pharmacotherapy ·doi:10.1517/14656566.7.15.2155

The use of cetrorelix within ovarian-stimulation protocols demonstrates several advantages compared with gonadotropin-releasing hormone (GnRH) agonist-containing protocols, which include, for example, significantly less time for analogue tr…

nonrandomized-trial 2006
Fertility and sterility ·doi:10.1016/j.fertnstert.2006.05.043

OBJECTIVE: To compare the amount of regulated upon activation, normal T cell expressed and secreted (RANTES) and monocyte chemotactic protein 1 (MCP-1) in follicular fluid (FF) of patients with and without endometriosis and to determine the…

nonrandomized-trial 2006
Archives of gynecology and obstetrics ·doi:10.1007/s00404-005-0112-0

Ovarian hyperstimulation syndrome (OHSS) is a severe complication of ovarian stimulation. No reliable test exists to predict the syndrome. The objective of the present prospective observational study was to examine vascular endothelial grow…

review 2005
Expert opinion on investigational drugs ·doi:10.1517/13543784.14.9.1085

Gonadotropin-releasing hormone (GnRH) stimulates the pituitary secretion of both luteinising hormone (LH) and follicle-stimulating hormone (FSH), and thus controls the hormonal and reproductive functions of the gonads. The blockade of the e…